agree...now everything is riding on the drug interaction study
about the only positive is that the 53% undetectable in naives is higher than historical undetectable rate at end of treatment in gen-1s on peg alone (35%, Hepatology. 2001 Aug;34(2):395-403)..so there is clearly efficacy to the drug but it certainly doesn't look like it can bump riba from the regimen
<< SVR rates were not. One SVR is still one SVR , and zero is still zero. SOC got 1 SVR from <<only>> 34 patients. NM283 got zero SVRs from 144 patients.>>
"1" is not a lot You imply that you can extrapolate to 4 SVR in 4x34 pts -- That seems like spinning to me.
Im no expert but the numbers of patients are very small to draw conclusions
maybe someone who knows statistics would opine
I think the response has been too negative. All of these drugs have limited responses No one realistically expected the drug to be used alone It's potential use in a cocktail- and mkt value has not changed much
Market Data 
Markets 
AI
